Can Regrowing the Aging Thymus Make Cancer Immunotherapy Work Better
A review weighs thymic regeneration strategies, from IL-7 to androgen blockade, against observational evidence linking a healthier thymus to better cancer immunotherapy outcomes.
Resumen
The thymus trains T cells, the immune system's cancer and infection fighters, but it shrinks steadily with age. This review explains why that happens: aging blood progenitors, damaged thymic epithelial cells, fat buildup, and rising sex hormones. It then ranks ways to rebuild the thymus by evidence level, including IL-7, KGF, BMP4, IL-22, RANKL, regulatory T cells, FOXN1-based bioengineering, and androgen blockade. Almost all of this work is in mice. Human observational data link healthier thymus imaging to lower mortality, lower lung cancer risk, and better immunotherapy outcomes. However, no randomized trial has shown that restoring the thymus improves cancer treatment, and one KGF trial in humans backfired.
Resumen detallado
Thymic involution is a central feature of immune aging. The thymus is where bone marrow progenitors become a diverse, self-tolerant T cell repertoire, and its output falls as it shrinks. This review asks whether regenerating it could help prevent cancer or improve immunotherapy.
The authors first describe the mechanisms. Involution begins in the first year of life, declining about 3% per year until age 35-45 and then about 1% per year. In mice, total thymocytes fall below 10% of their peak by 6 months. Drivers include lymphoid-biased progenitor loss, reduced FOXN1 in thymic epithelial cells, fat and fibrous replacement, lipotoxic signaling, rising IL-6 and LIF, and androgens. Atypical age-associated epithelial cells also sequester FGF and BMP signals. Two 2025 mouse studies implicated a local FGF21 axis.
Regenerative strategies are then graded by evidence. In mice, FOXN1 reprogrammed fibroblasts into functional thymic epithelium. IL-7 boosted thymic emigrants, and BMP4 drove a BMP4-FOXN1-DLL4 repair axis after injury. IL-22 from innate lymphoid cells aided epithelial repair, Treg transfer promoted regeneration, and RANKL expanded epithelial subsets after transplant. Nitazoxanide sped recovery after irradiation. Decellularized scaffolds seeded with stromal cells formed functional thymus in humanized mice.
Human evidence is thinner and sometimes negative. In the randomized CAMTHY trial, palifermin (KGF) given around alemtuzumab reduced naive CD4 T cells, recent thymic emigrants, and sjTRECs versus placebo, and the trial ended early. Leuprolide increased thymic function and TREC levels in prostate cancer patients and aided T cell reconstitution after stem cell transplantation. Combining KGF with leuprolide worked better in mouse transplant models.
Observational studies link better radiographic thymic health to lower all-cause mortality and lung cancer incidence, while adult thymectomy was associated with higher mortality and cancer risk. Further cohorts connect thymic health, TCR diversity, and tumor infiltration to immunotherapy outcomes. The authors stress that this makes thymic health a candidate biomarker, not proof that restoring it improves response. Cancer itself can also cause reversible thymic involution in mouse models.
Caveats are substantial. Nearly all interventions are preclinical, no randomized trial shows improved immunotherapy outcomes, and androgen suppression carries endocrine and metabolic harms. Thymic effects on tumor incidence differ from effects on established tumors, which also depend on peripheral T cells and other cells.
Hallazgos clave
- Thymic involution starts in the first year of life, progressing about 3% per year until age 35-45, then about 1% per year
- Mouse thymocytes fall below 10% of peak by 6 months of age
- CAMTHY randomized trial: palifermin (KGF) lowered naive CD4 T cells, RTEs, and sjTRECs versus placebo and was stopped early
- Leuprolide raised thymic function and TREC levels in prostate cancer patients
- FOXN1 induction delayed thymic involution and expanded the epithelial compartment in mice
- Better radiographic thymic health was associated with lower all-cause mortality and lung cancer incidence
- No randomized trial shows thymus-directed therapy improves cancer immunotherapy outcomes
Metodología
This is a narrative review of preclinical and human literature on thymic involution and regeneration, organized by mechanism and strategy and graded by evidence level. It includes no new data, sample sizes, or pooled statistics. Cited human work includes one randomized trial (CAMTHY), small androgen-deprivation studies, and observational imaging cohorts.
Limitaciones del estudio
Most regenerative data come from mice and may not translate, as the CAMTHY result shows. Human evidence is observational or limited to prostate cancer and transplant settings, which cannot establish causation or generalize broadly. As a narrative review, it may be subject to selection bias.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte:
